Table 1.
Baseline Clinical Characteristics of the Patients
| Characteristics | N = 583 |
|---|---|
| Age, y | |
| Median (range) | 72 (30–95) |
| Sex, n (%) | |
| Male | 224 (38.4) |
| Female | 359 (61.6) |
| Smoking status, n (%) | |
| Never | 325 (55.8) |
| Current | 34 (5.8) |
| Former | 224 (38.4) |
| ECOG performance status, n (%) | |
| 0 | 216 (37.1) |
| 1 | 281 (48.2) |
| 2 | 60 (10.3) |
| 3 | 20 (3.4) |
| 4 | 2 (0.3) |
| Missing | 4 (0.7) |
| Histologic type, n (%) | |
| Adenocarcinoma | 571 (97.9) |
| Squamous | 9 (1.5) |
| NOS | 2 (0.3) |
| LCNEC | 1 (0.2) |
| Overall disease classification, n (%) | |
| Metastatic | 395 (67.8) |
| Recurrence | 169 (29.0) |
| Locally advanced | 19 (3.3) |
| CNS metastases, n (%) | |
| Yes | 169 (29.0) |
| No | 414 (71.0) |
| EGFR mutation type, n (%) | |
| Exon 19 deletion | 285 (48.9) |
| L858R | 266 (45.6) |
| Others | 32 (5.5) |
CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group; LCNEC, large cell neuroendocrine carcinoma; NOS, not otherwise specified.